Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Analysts' Actions: EXPE, WAG, UAL, RE

Analysts' Actions: EXPE, WAG, UAL, RE

Here are today's top research calls.

Salix Pharmaceuticals Completes Acquisition Of Oceana Therapeutics

Salix Pharmaceuticals Completes Acquisition Of Oceana Therapeutics

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Oceana Therapeutics, LLC today closed a transaction whereby Salix acquired all of the outstanding stock of Oceana Therapeutics, Inc.

Salix Stock Gaps Up On Today's Open (SLXP)

Salix Stock Gaps Up On Today's Open (SLXP)

Shares of Salix Pharmaceuticals (Nasdaq:SLXP) were gapping up Tuesday morning with an open price 10.3% higher than Monday's closing price. The stock closed at $43.23 yesterday and opened today's trading at $47.70.

Salix Pharmaceuticals Announces NDA Submission For Crofelemer For The Treatment Of HIV-Associated Diarrhea

Salix Pharmaceuticals Announces NDA Submission For Crofelemer For The Treatment Of HIV-Associated Diarrhea

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has submitted to the U.

Salix Pharmaceuticals To Present At Oppenheimer Healthcare Conference

Salix Pharmaceuticals To Present At Oppenheimer Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The Oppenheimer 22 nd Annual Healthcare Conference in New York, NY on Tuesday, December 13, 2011 at 1:35 p.

Salix Stock Gaps Up On Today's Open (SLXP)

Salix Stock Gaps Up On Today's Open (SLXP)

Shares of Salix Pharmaceuticals (Nasdaq:SLXP) were gapping up Thursday morning with an open price 10.6% higher than Wednesday's closing price. The stock closed at $33.90 yesterday and opened today's trading at $37.50.

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) has been upgraded by TheStreet Ratings from a hold to buy.

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Drugs Winner

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Drugs Winner

Salix Pharmaceuticals was a winner within the drugs industry, rising $2.07 (6%) to $36.72 on heavy volume.

8 Stocks Rising on Unusual Volume

8 Stocks Rising on Unusual Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Salix Pharmaceuticals To Acquire Oceana Therapeutics

Salix Pharmaceuticals To Acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics,...

Salix Pharmaceuticals Reports 3Q2011 Results And Raises 2011 Guidance

Salix Pharmaceuticals Reports 3Q2011 Results And Raises 2011 Guidance

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

Salix Pharmaceuticals Previews Data Slated For Presentation At 62nd Annual Meeting Of The American Association For The Study Of Liver Diseases

Salix Pharmaceuticals Previews Data Slated For Presentation At 62nd Annual Meeting Of The American Association For The Study Of Liver Diseases

Salix Pharmaceuticals, Inc. (NASDAQ:SLXP) today announced that the 62 nd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting ® 2011), being held in San Francisco, CA,...

Salix Pharmaceuticals To Present At Two Investment Conferences In November

Salix Pharmaceuticals To Present At Two Investment Conferences In November

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two health care investment conferences during November 2011.

Salix Pharmaceuticals Previews American College Of Gastroenterology 2011

Salix Pharmaceuticals Previews American College Of Gastroenterology 2011

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of several of the Company’s products – including rifaximin,...

Salix Pharmaceuticals Announces 3Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 3Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will report third quarter 2011 financial results following the close of the U.

Salix Stock Hits New 52-Week Low (SLXP)

Salix Stock Hits New 52-Week Low (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week low Thursday as it is currently trading at $25.69, below its previous 52-week low of $26.46 with 17,656 shares traded as of 9:36 a.m. ET. Average volume has been 899,500 shares over the past 30 days.

Salix Stock Hits New 52-Week Low (SLXP)

Salix Stock Hits New 52-Week Low (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week low Monday as it is currently trading at $26.79, below its previous 52-week low of $26.80 with 234,479 shares traded as of 10:40 a.m. ET. Average volume has been 843,700 shares over the past 30 days.

Salix Pharmaceuticals To Present At Three Investment Conferences In September

Salix Pharmaceuticals To Present At Three Investment Conferences In September

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three health care investment conferences during September 2011.

Progenics And Salix Announce FDA Acceptance Of SNDA Filing For RELISTOR® In Patients With Non-Cancer Pain

Progenics And Salix Announce FDA Acceptance Of SNDA Filing For RELISTOR® In Patients With Non-Cancer Pain

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals, Ltd.

Salix Stock Hits New 52-Week Low (SLXP)

Salix Stock Hits New 52-Week Low (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week low Thursday as it is currently trading at $28.94, below its previous 52-week low of $29.03 with 600,904 shares traded as of 3:01 p.m. ET. Average volume has been 785,100 shares over the past 30 days.

Salix Stock Hits New 52-Week Low (SLXP)

Salix Stock Hits New 52-Week Low (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week low Tuesday as it is currently trading at $30.88, below its previous 52-week low of $31.29 with 1.3 million shares traded as of 11:52 a.m. ET. Average volume has been 741,700 shares over the past 30 days.

Salix Pharmaceuticals Reports 2Q2011 Results

Salix Pharmaceuticals Reports 2Q2011 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2011 and other business updates.

Salix Pharmaceuticals Announces 2Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 2Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2011 financial results following the close of the U.

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three health care investment conferences during June 2011.

Salix Pharmaceuticals Reviews Data Presentations At American Pain Society Annual Meeting

Salix Pharmaceuticals Reviews Data Presentations At American Pain Society Annual Meeting

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced findings from two analyses of a Phase 3 open-label study of RELISTOR ® (methylnaltrexone bromide) presented at the 30 th Annual Scientific Meeting of the...

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2011

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2011

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that numerous presentations describing the investigation of several of the Company’s products – including rifaximin and MOVIPREP ® -- occurred...

Salix Pharmaceuticals Receives Lawsuit From Napo Pharmaceuticals

Salix Pharmaceuticals Receives Lawsuit From Napo Pharmaceuticals

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that Napo Pharmaceuticals, Inc.

Salix Pharmaceuticals Reports 1Q2011 Results

Salix Pharmaceuticals Reports 1Q2011 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2011.

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two health care investment conferences during May 2011.